BiotechTube
Home/Denali Therapeutics/V. Michael Weinreb
VM

V. Michael Weinreb

Board Member

Denali Therapeutics

Therapeutic Areas

Neurodegenerative DiseasesLysosomal Storage Disorders

Denali Therapeutics Pipeline

DrugIndicationPhase
DNL310Hunter syndrome (MPS II)Phase 2/3
BIIB122/DNL151Parkinson's diseasePhase 3
DNL343Amyotrophic Lateral Sclerosis (ALS)Phase 2/3
SAR443820/DNL788Multiple Sclerosis, ALSPhase 2

Leadership Team at Denali Therapeutics

RJ
Ryan J. Watts
Chief Executive Officer
AO
Alexander O. Schuth
Chief Operating Officer
CH
Carole Ho
Chief Medical Officer
MT
Marc Tessier-Lavigne
Board Member
View full Denali Therapeutics profile